Furosemide Price Index: Trend, Chart, Market Analysis and Forecast 2026
Author : ChemAnalyst Data | Published On : 13 Oct 2026
According to ChemAnalyst, The Furosemide Price Index in the Asia-Pacific (APAC) region increased quarter-over-quarter in Q2 2026, reflecting rising production costs and continued pressure on pharmaceutical manufacturing inputs. China experienced higher producer input costs during the quarter, while India recorded a Furosemide price of USD 4,950/MT on an FOB basis in June 2026. Regional market conditions were influenced by manufacturing expenses, industrial activity, inflation trends, and the balance between pharmaceutical demand and supply availability.
China's Producer Price Index (PPI) increased by 4.1% year-over-year in June 2026, indicating higher costs across the industrial production chain. This increase contributed to the upward movement in Furosemide production expenses, particularly through the costs associated with chemical intermediates, energy, utilities, and other manufacturing inputs. As pharmaceutical ingredient producers faced higher operating expenses, the market experienced continued upward pressure on prices.
Despite the increase in production costs, the demand outlook for Furosemide in APAC remained broadly stable during Q2 2026. China's unemployment rate stood at 5.0% in June 2026, indicating relatively steady labor market conditions. Although unemployment is not a direct measure of pharmaceutical demand, stable employment conditions can support household purchasing power and access to healthcare services. This helped maintain a relatively consistent demand environment for essential medicines.
In India, the FOB price of Furosemide settled at USD 4,950/MT in June 2026. The Indian market benefited from comparatively stable industrial activity, with industrial production growing by 5.3% year-over-year in June 2026. Expanding industrial output supported manufacturing continuity and helped maintain the availability of pharmaceutical production inputs. However, the overall impact on Furosemide prices remained dependent on the cost of active pharmaceutical ingredient (API) production, procurement conditions, and the availability of intermediate chemicals.
India's Consumer Price Index (CPI) increased by 1.0% year-over-year in June 2026, helping limit pressure from general inflation on selected non-API operating expenses. Nevertheless, relatively subdued retail sales growth of 1.0% during the month suggested that consumer spending remained restrained. While retail activity does not directly determine pharmaceutical ingredient prices, it can provide a broader indication of consumer demand conditions and potential pressure on downstream medicine markets.
The combination of increasing production costs and stable pharmaceutical requirements kept the regional Furosemide Price Index under upward pressure during Q2 2026. Producers faced the challenge of managing rising input expenses while maintaining competitive pricing and dependable supply to pharmaceutical manufacturers. Looking ahead, the Furosemide Price Index in APAC is expected to remain exposed to cost-related increases if chemical inputs, utilities, and manufacturing expenses continue to rise.
Get Real Time Online for Furosemide Prices: https://www.chemanalyst.com/Pricing-data/furosemide-1495
Why Did Furosemide Prices Change in June 2026 in APAC?
The increase in Furosemide prices in APAC during June 2026 was primarily associated with higher producer input costs and continued pressure on pharmaceutical manufacturing expenses. China's 4.1% year-over-year PPI increase indicated a more expensive industrial cost environment, affecting the economics of producing chemical intermediates and pharmaceutical ingredients.
At the same time, India's expanding industrial production supported manufacturing activity and supply-chain continuity. The 5.3% annual growth in industrial production helped maintain a supportive environment for pharmaceutical production, although it did not eliminate the effects of rising input costs. CPI inflation of 1.0% also moderated general operating-cost pressure, while retail sales growth of 1.0% pointed to subdued consumer spending.
Stable labor market conditions, reflected in China's 5.0% unemployment rate, helped underpin the broader demand environment. Consequently, the June 2026 Furosemide market reflected a combination of higher production expenses, relatively stable pharmaceutical demand, and region-specific differences in manufacturing and consumer conditions.
Furosemide Prices in North America
The Furosemide Price Index in North America increased quarter-over-quarter in Q2 2026, supported by higher producer costs, elevated chemical input prices, and disruptions affecting global feedstock availability. The United States experienced significant cost pressures throughout the quarter as geopolitical conflicts and changes in energy markets influenced the prices of industrial chemicals and pharmaceutical manufacturing inputs. These developments increased the cost burden for producers and contributed to the upward movement in Furosemide prices.
The US Producer Price Index rose by 5.5% year-over-year in June 2026, highlighting the inflationary pressure affecting industrial goods and production-related services. For Furosemide manufacturers, higher producer prices can translate into increased procurement expenses for chemical intermediates, solvents, reagents, packaging materials, utilities, and other manufacturing requirements. The extent of the impact depends on each producer's sourcing arrangements, production efficiency, and ability to secure inputs through existing supply agreements.
Global chemical markets also experienced significant price increases during Q2 2026. Geopolitical conflicts affected crude oil markets, while disruptions to feedstock supply and international trade flows increased uncertainty for chemical manufacturers. These developments created challenges for pharmaceutical supply chains by raising transportation expenses, extending procurement lead times, and increasing the cost of selected production inputs. Although Furosemide is a pharmaceutical compound rather than a direct crude oil derivative, its manufacturing economics can be affected by broader changes in chemical, energy, and logistics markets.
Demand for Furosemide remained stable in North America during Q2 2026, supported by an upward trend in US healthcare spending. Furosemide is a loop diuretic used in the treatment of conditions involving fluid retention, including certain cases of heart failure, kidney disorders, and liver disease. Its established therapeutic role supports recurring demand from hospitals, healthcare providers, and pharmaceutical distributors. As a result, demand for the active pharmaceutical ingredient is influenced by treatment requirements, medicine production schedules, inventory management, and procurement contracts.
Economic indicators also provided support to the broader demand environment. US retail sales increased by 6.9% year-over-year in May 2026, reflecting growth in consumer spending. Although retail sales are not a direct indicator of pharmaceutical ingredient consumption, stronger retail activity can provide a broader indication of economic resilience. The US unemployment rate stood at 4.2% in June 2026, suggesting relatively stable labor market conditions that may help support healthcare access and household purchasing capacity.
However, the increase in the Consumer Price Index to 3.5% year-over-year in June 2026 added pressure to the wider operating environment. Higher prices for energy, transportation, labor-related services, and other business expenses can affect pharmaceutical manufacturers and distributors. When combined with rising producer prices and international supply-chain uncertainty, these factors contributed to a more expensive procurement environment for Furosemide.
The overall North American market therefore reflected a combination of increasing manufacturing expenses and stable underlying pharmaceutical demand. Producers and buyers were required to manage cost volatility while maintaining reliable supply and meeting production commitments. The upward movement in the Furosemide Price Index during Q2 2026 highlighted the importance of raw-material sourcing, supplier diversification, inventory planning, and contractual flexibility.
Looking forward, North American Furosemide prices are expected to remain sensitive to producer inflation, international chemical prices, energy costs, and pharmaceutical procurement activity. If feedstock availability remains constrained and manufacturing expenses continue to rise, producers may face further pressure to adjust prices. Conversely, improved logistics, easing input costs, and more balanced inventories could moderate price increases.
Why Did Furosemide Prices Change in June 2026 in North America?
Furosemide prices in North America increased in June 2026 primarily because of higher production costs and continued volatility in global chemical markets. The US PPI rose by 5.5% year-over-year, indicating significant cost pressure across the industrial economy. This environment increased expenses associated with sourcing chemical inputs and maintaining pharmaceutical manufacturing operations.
Geopolitical conflicts and feedstock supply disruptions further influenced the market by creating uncertainty around crude oil prices, chemical availability, and transportation costs. These factors affected the wider pharmaceutical supply chain, even where individual ingredients were not directly linked to petroleum-based feedstocks.
At the same time, the demand outlook remained relatively stable because of continued healthcare spending and the established medical use of Furosemide. Stronger retail sales and a 4.2% unemployment rate supported the broader economic environment, although neither indicator directly measures pharmaceutical API demand. With CPI inflation reaching 3.5% in June 2026, producers continued to face pressure from elevated operating expenses, reinforcing the upward trend in the regional Furosemide Price Index.
Furosemide Prices in Europe
The Furosemide Price Index in Europe increased quarter-over-quarter in Q2 2026, driven by higher production expenses, firming feedstock prices, and shortages of selected intermediate chemicals. Germany remained an important market for evaluating regional price movements, as the country's pharmaceutical and chemical manufacturing industries were affected by elevated energy expenses and uneven industrial performance. These factors contributed to a more challenging cost environment for Furosemide producers and supported the upward movement in prices during the quarter.
Germany's Producer Price Index increased by 2.2% year-over-year in May 2026, indicating rising prices across the domestic producer economy. The increase added pressure to manufacturing expenses, including costs associated with chemical inputs, utilities, industrial services, and other production requirements. For Furosemide manufacturers, higher input prices can reduce production margins, particularly when procurement contracts and selling prices do not adjust at the same pace.
Feedstock developments also influenced the European pharmaceutical manufacturing environment. Naphtha prices firmed in April 2026, while elevated energy costs increased the expense of operating chemical production facilities. Naphtha is an important feedstock for several segments of the petrochemical industry, and changes in its price can influence the wider cost structure of chemical intermediates and industrial materials. Although the relationship between naphtha prices and Furosemide production is indirect, broader feedstock inflation can affect the cost of materials and services used throughout the pharmaceutical supply chain.
Material shortages affecting intermediate products in Germany's chemical industry intensified in May 2026. These shortages created additional procurement challenges for manufacturers that depended on consistent deliveries of chemical inputs. When the availability of intermediates becomes restricted, producers may face longer lead times, higher sourcing expenses, and increased inventory requirements. Such conditions can contribute to upward price pressure even when final-product demand remains relatively stable.
General inflation added another layer of cost pressure. Germany's Consumer Price Index rose by 2.3% year-over-year in June 2026, increasing expenses across parts of the broader business environment. Higher operating costs can affect pharmaceutical manufacturing through utilities, logistics, packaging, maintenance, and other essential services. As a result, producers had to balance input-cost increases against the need to maintain competitive prices and reliable supply to pharmaceutical customers.
Despite these challenges, demand for Furosemide in Germany strengthened during Q2 2026. An aging population and continuing medical requirements supported the need for medicines used to manage fluid retention associated with certain cardiovascular, renal, and hepatic conditions. Furosemide's established therapeutic role helps sustain demand from pharmaceutical manufacturers supplying hospitals, pharmacies, and healthcare providers.
Economic indicators provided a mixed picture of downstream market conditions. German retail sales increased by 1.8% in May 2026, while the unemployment rate remained at 3.8%, indicating a relatively stable labor market. These indicators offered some support to the broader economic environment, although pharmaceutical demand is more directly influenced by healthcare requirements, prescription patterns, reimbursement arrangements, and medicine procurement.
Industrial conditions, however, remained challenging. Germany's industrial production was unchanged at 0.0% in May 2026, while the Manufacturing Index contracted in June 2026. Weak industrial momentum may limit manufacturing efficiency and reduce the ability of some suppliers to expand output quickly. In the chemical sector, these conditions can complicate production planning and supply-chain coordination, especially when input availability is already constrained.
Consumer confidence also weakened in June 2026, creating a contrast with the stronger demand observed in parts of the pharmaceutical market. Lower consumer confidence may affect discretionary spending, but essential medicines often follow different demand patterns because their use is determined primarily by medical needs. Consequently, pharmaceutical demand for Furosemide remained supported even as broader economic indicators showed signs of weakness.
The European Furosemide market therefore experienced a combination of higher manufacturing costs, restricted intermediate availability, and stable-to-strengthening pharmaceutical demand. These conditions supported the quarter-over-quarter increase in the Furosemide Price Index. Market participants continued to face the challenge of maintaining dependable supplies while managing energy, procurement, and operating expenses.
Looking ahead, European Furosemide prices are expected to remain firm if producer costs stay elevated and intermediate chemical availability remains constrained. The future direction of prices will depend on feedstock movements, energy expenses, manufacturing recovery, and pharmaceutical procurement requirements. Improvements in industrial output and the availability of chemical inputs could ease cost pressure, while renewed supply disruptions may reinforce the upward trend.
Why Did Furosemide Prices Change in June 2026 in Europe?
Furosemide prices in Europe increased in June 2026 because of persistent manufacturing cost pressures and continued challenges across the German chemical supply chain. Germany's PPI rose by 2.2% year-over-year in May 2026, increasing the cost base for industrial producers. At the same time, firmer naphtha prices in April and elevated energy expenses contributed to higher production costs across the wider chemical industry.
Shortages of intermediate products added to procurement uncertainty and made it more difficult for manufacturers to secure inputs consistently. These supply-side challenges supported upward price pressure, particularly when producers faced higher expenses for materials, utilities, and logistics.
Demand conditions also contributed to the market's direction. Germany's aging population and continuing medical treatment requirements supported pharmaceutical consumption, helping maintain demand for Furosemide. Retail sales growth of 1.8% in May and unemployment of 3.8% provided additional context for the broader economic environment, although these figures do not directly measure pharmaceutical ingredient demand.
Meanwhile, CPI inflation reached 2.3% in June 2026, adding to operating-cost pressure. Industrial production remained unchanged in May, and manufacturing conditions weakened in June, limiting the potential for a rapid improvement in industrial supply. Together, these factors supported the upward movement in the European Furosemide Price Index during Q2 2026.
Book A Demo for Furosemide Prices: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Furosemide
Furosemide Price Forecast: Market Outlook
The Furosemide price outlook for the coming quarters will depend primarily on production costs, the availability of chemical intermediates, energy-market developments, and pharmaceutical demand. Across APAC, North America, and Europe, rising producer expenses were a common factor behind the upward movement in the Furosemide Price Index during Q2 2026. However, the intensity of these pressures differed according to regional manufacturing conditions, inflation levels, and supply-chain dynamics.
In APAC, the Furosemide Price Index is expected to remain exposed to higher input costs, particularly if producer inflation in China persists. India's industrial growth and relatively subdued consumer inflation may help support manufacturing continuity, although the direction of FOB prices will continue to depend on API production economics and export-market conditions.
In North America, the outlook will remain sensitive to chemical price volatility, geopolitical developments, feedstock availability, and inflation in manufacturing services. Continued healthcare demand may provide a stable foundation for the market, but higher procurement and logistics expenses could maintain upward price pressure.
In Europe, elevated energy costs and intermediate chemical shortages remain important variables. A recovery in industrial production and improved feedstock availability could ease manufacturing expenses. However, persistent producer inflation and continued pharmaceutical demand may keep prices firm.
Overall, the Furosemide Price Index is forecast to remain under upward pressure if input costs continue to rise and supply-chain constraints persist. Buyers should monitor supplier quotations, raw-material availability, regional trade conditions, and procurement lead times to manage potential price fluctuations. Producers, meanwhile, may benefit from diversifying suppliers, improving production efficiency, and maintaining flexible sourcing arrangements.
About Us:
Welcome to ChemAnalyst, a next–generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as “Product Innovator of the Year 2023” and ranked among the “Top 100 Digital Procurement Solutions Companies,” we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.
Contact Us:
Address:
420 Lexington Avenue, Suite 300 New York, NY 10170 United States
Phone: +1 332 258 6602
Email: [email protected]
Website: https://www.chemanalyst.com/
LinkedIn: https://www.linkedin.com/company/chemanalyst/
Facebook: https://www.facebook.com/ChemAnalysts/
Twitter: https://x.com/chemanalysts
YouTube: https://www.youtube.com/@chemanalyst
Instagram: https://www.instagram.com/chemanalyst_
